Watanabe H, Levene R Z, Bernstein M R
Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977 Jan-Feb;83(1):69-77.
At the inception of this study, 6-hydroxydopamine (6-HD) was administered to 137 eyes of 100 glaucoma patients by subconjunctival injection (27 applications) and later by iontophoresis (202 applications). Eighty-four patients were receiving maximum medical therapy, and 24 had had previous glaucoma surgery. Seventy-seven had primary open-angle glaucoma. In 49 patients with data adequate for analysis, 6-HD therapy was effective in 41%, questionable in 31%, and not effective in 28%. The median peak-pressure drop was 13 mm Hg from a baseline of 26 by subconjunctival injection and 6 mm Hg from a baseline of 24 by iontophoresis. The median effective period before return to baseline pressure was 2.5 months. There was a direct correlation between the effectiveness of epinephrine therapy with and without 6-HD. Iontophoresis is a much more practical method for the administration of 6-HD.
在本研究开始时，对100例青光眼患者的137只眼进行了6-羟基多巴胺（6-HD）治疗，其中27次采用结膜下注射，202次采用离子导入法。84例患者接受了最大程度的药物治疗，24例曾接受过青光眼手术。77例为原发性开角型青光眼。在49例有足够数据可供分析的患者中，6-HD治疗有效率为41%，效果存疑率为31%，无效者为28%。结膜下注射时，眼压从基线26 mmHg下降的中位数峰值为13 mmHg；离子导入法时，眼压从基线24 mmHg下降的中位数峰值为6 mmHg。恢复至基线眼压前的中位有效期为2.5个月。使用和不使用6-HD的肾上腺素治疗效果之间存在直接相关性。离子导入法是一种更实用的6-HD给药方法。
